{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T09:00:57Z","timestamp":1780736457258,"version":"3.54.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"DOI":"10.7759\/cureus.110337","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:18:06Z","timestamp":1780733886000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis\/Renal Dysfunction, and Organomegaly (TAFRO) Syndrome Refractory to Treatment With Combination Therapy of Corticosteroid, Tocilizumab, and Rituximab: A Case Report"],"prefix":"10.7759","author":[{"given":"Akihiro","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-1979-1","article-title":"Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version","volume":"103","author":"Masaki Y","year":"2016","unstructured":"Masaki Y, Kawabata H, Takai K, et al.. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016, 103:686-92. 10.1007\/s12185-016-1979-1","journal-title":"Int J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25554","article-title":"Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?","volume":"94","author":"Fujimoto S","year":"2019","unstructured":"Fujimoto S, Sakai T, Kawabata H, et al.. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?. Am J Hematol. 2019, 94:975-83. 10.1002\/ajh.25554","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3075","article-title":"TAFRO syndrome: A disease that known is half cured","volume":"41","author":"Chen T","year":"2023","unstructured":"Chen T, Feng C, Zhang X, Zhou J. TAFRO syndrome: A disease that known is half cured. Hematol Oncol. 2023, 41:310-22. 10.1002\/hon.3075","journal-title":"Hematol Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04762-6","article-title":"Castleman disease and TAFRO syndrome","volume":"101","author":"Masaki Y","year":"2022","unstructured":"Masaki Y, Arita K, Sakai T, et al.. Castleman disease and TAFRO syndrome. Ann Hematol. 2022, 101:485-90. 10.1007\/s00277-022-04762-6","journal-title":"Ann Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki N","year":"2016","unstructured":"Iwaki N, Fajgenbaum DC, Nabel CS, et al.. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016, 91:220-6. 10.1002\/ajh.24242","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12051076","article-title":"Unraveling TAFRO syndrome: an in-depth look at the pathophysiology, management, and future perspectives","volume":"12","author":"Caballero JC","year":"2024","unstructured":"Caballero JC, Conejero N, Solan L, et al.. Unraveling TAFRO syndrome: an in-depth look at the pathophysiology, management, and future perspectives. Biomedicines. 2024, 12:10.3390\/biomedicines12051076","journal-title":"Biomedicines"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1834094","article-title":"Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman's disease","volume":"62","author":"Ebisawa K","year":"2021","unstructured":"Ebisawa K, Shimura A, Honda A, et al.. Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman's disease. Leuk Lymphoma. 2021, 62:614-9. 10.1080\/10428194.2020.1834094","journal-title":"Leuk Lymphoma"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/360851-a-case-of-thrombocytopenia-anasarca-fever-reticulin-fibrosisrenal-dysfunction-and-organomegaly-tafro-syndrome-refractory-to-treatment-with-combination-therapy-of-corticosteroid-tocilizumab-and-rituximab-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:18:06Z","timestamp":1780733886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/360851-a-case-of-thrombocytopenia-anasarca-fever-reticulin-fibrosisrenal-dysfunction-and-organomegaly-tafro-syndrome-refractory-to-treatment-with-combination-therapy-of-corticosteroid-tocilizumab-and-rituximab-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.110337","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,6]]}}}